Ablation of atrial fibrillation: awaiting the new paradigm.
Ellenbogen
Kenneth A
KA
Wood
Mark A
MA
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000401:mortality / Q000523:psychology / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods; D004617:Embolism / Q000209:etiology; D005500:Follow-Up Studies; D006306:Health Surveys; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D009017:Morbidity; D018579:Patient Selection; D011667:Pulmonary Veins / Q000601:surgery; D011788:Quality of Life; D012008:Recurrence; D012107:Research Design / Q000592:standards; D020521:Stroke / Q000209:etiology; D016019:Survival Analysis; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents